Amid North America Push, DreaMed Appoints New General Manager

Through fostering partnerships with large organizations in the U.S. healthcare system, newly appointed General Manager Ryan Hovey will spearhead the company’s B2B commercial efforts

TEL AVIV, Israel--(BUSINESS WIRE)-- DreaMed Diabetes Ltd., the developer of personalized, AI-based diabetes management solutions, announces the hiring of Ryan Hovey to lead and execute DreaMed’s commercial strategy in the U.S. healthcare market. Ryan brings with him a wealth of experience in health solutions and business leadership, with a great track record of success leading growth strategies, new product launches and expansions, as well as establishing the infrastructure required to rapidly grow a business.

Before joining DreaMed, Ryan was Vice President of Providers Solutions at Optum’s Population Health Solutions business, with end-to-end responsibility to launch and scale a portfolio of population health products in the provider market. Prior to this, he led Optum’s Transplant Solutions business, where he launched multiple product expansions and transformed the go-to market strategy from point products to an end-to-end solution. Ryan’s initial role at Optum was leading the new concept development funnel, where he instituted the process for early stage feasibility and prioritization, as well as taking ideas from concept, to pilot, to launch. He holds an MBA from the Ross School of Business at the University of Michigan, and a Bachelor of Arts degree from the University of San Diego.

DreaMed is expanding its operations across the U.S., integrating its insulin management technology into various clinics situated across the country, which will embed DreaMed Advisor(r) into their current protocols, helping them to provide diabetes patients with a personalized treatment solution.

“We’re elated to have Ryan on board,” says Eran Atlas, CEO of DreaMed Diabetes. “He brings a wealth of experience to our North American efforts, specifically within the US health system, and will help take our commercial activity to new heights. North America is a hugely strategic market for us, where interest in our solution is accelerating at a pace while clinics are increasingly utilizing our service.”

“I’m glad to join DreaMed during such an exciting time,” says Ryan. “I’m especially looking forward to improving people’s lives by cultivating FDA-cleared, AI-based, clinically validated and remote personalized diabetes treatment optimization solutions in the U.S., further expanding on DreaMed’s impressive ascent."

About DreaMed Diabetes

DreaMed Diabetes is a medical device company providing personalized diabetes treatment optimization solutions. The company was established in 2014 and commercialized its automated insulin delivery to Medtronic Diabetes, which recently received CE mark. Ever since, DreaMed Diabetes has been vigorously working on the DreaMed Advisor(r) portfolio, decision support tools in the diabetes management space. DreaMed became the first and only company in the world to receive a CE Mark and FDA clearance for DreaMed Advisor Pro, a decision support system in Type I diabetes patients using data from CGM/SMBG and insulin pumps. The company is continuing to develop the DreaMed Advisor portfolio which will aid all people living with diabetes no matter the insulin therapy or diabetes type and their healthcare professionals to provide personalized insulin therapy. For more information please visit https://www.dreamed-diabetes.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200824005135/en/